The European Medicines Agency's CHMP has shown support for Eli Lilly's Alzheimer’s drug Kisunla after reversing an earlier rejection, approving it for patients who are APOE4 heterozygotes or non-carriers. This marks a significant regulatory development following initial concerns over risks such as brain edema and hemorrhage. Meanwhile, the CHMP also recommended Gilead's twice-yearly HIV prevention injection, expanding therapeutic options. However, other decisions showed caution, maintaining a complex regulatory landscape for innovative therapies in Europe.